<DOC>
	<DOCNO>NCT02082327</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics IV migalastat HCl alone determine absolute bioavailability oral migalastat HCl compare IV administer migalastat HCl healthy volunteer . The data study help u understand migalastat work body help u determine would effective dose future study migalastat hydrochloride .</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate Safety Migalastat Hydrochloride Given Intravenously Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Males females 18 45 year age . Body weight range ≥ 50 kg ≤ 100 kg BMI within range 18.5 29.9 kg/m2 . Healthy determine responsible experienced physician , base medial evaluation . Male female subject childbearing potential agree adhere contraception requirement . Capable give write informed consent . History sensitivity migalastat HCl related iminosugars ( eg , miglitol , miglustat ) , significant drug allergy . Past medical history , physical examination finding , clinically significant abnormality may put subject risk interfere outcome variable . Positive prestudy drug/alcohol screen . Pregnant lactating female . The subject participate clinical trial receive investigational product within 60 day prior first dose day current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Fabry Disease</keyword>
	<keyword>Fabry</keyword>
	<keyword>Lysosomal storage disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>Amicus</keyword>
	<keyword>migalastat HCl</keyword>
	<keyword>migalastat</keyword>
	<keyword>AT1001</keyword>
</DOC>